• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • NICE rejects adjuvant use of Perjeta post-surgery pharmatimes
    June 21, 2018
    The National Institute for Health and Care Excellence says adjuvant use of Roche’s breast cancer drug Perjeta in patients who have had surgery is not cost effective for the NHS.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service